Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selumetinib in children with NF1 and plexiform neurofibroma or optic pathway glioma
NCT03326388Phase 2Completed
- Sponsor
- Great Ormond Street Hospital
- Start
- Sep 2019
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of selumetinib in neurofibromatosis type 1 (NF1), plexiform neurofibroma (PN), optic pathway glioma (OPG), sponsored by Great Ormond Street Hospital. Started Sep 2019; status: completed.
02
Drugs
selumetinib
03
Conditions
neurofibromatosis type 1 (NF1)plexiform neurofibroma (PN)optic pathway glioma (OPG)
Beyond the preview
Go deeper on NCT03326388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03326388.